Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

Restrictive eligibility criteria are the second leading cause preventing patients from enrolling in cancer clinical trials.  FDA recently issued draft guidance encouraging trial sponsors to use a science-based approach that would allow a wider variety of patients to participate in cancer clinical

Over 80 organizations are urging Congress to take up and pass reform to modernize the oversight of diagnostic test. 

Biomarker testing is critical to successfully realizing personalized medicine, both through the selection of appropriate targeted therapies as well as by directing patients to relevant clinical trials.  This report examines the private payer landscape of coverage for tumor biomarker tests in lung

Cancer registries provide high quality cancer data to inform policy at the local, state, and national levels. That National Program of Cancer Registries (NPCR) provides technical, operational, and financial support to most state cancer registries to help ensure data collected is representative of the U.S. population.

ACS CAN strongly believes that clinical trials are the key step towards advancing potential new cancer treatments from the research setting to the cancer care clinic, and that patient enrollment is critical to this success. Clinical trial matching improves enrollment by identifying a list of potential trials for which patients may be eligible. ACS CAN strongly supports NCI’s ongoing efforts to improve both its clinical trials reporting program (CTRP) database and functionalities within In this letter, we identify areas of need and potential opportunities for NCI to improve clinical trial matching.

Clinical trials are pivotal to advancements in cancer treatment, but patient enrollment in these trials remains a challenge. Clinical trial matching services facilitate patient enrollment in clinical trials by identifying potential trials for interested patients and their proxies (e.g., caregivers and providers), and in some cases by providing other support services such as educational materials or personnel who can answer questions or assist patients.

Leading health care companies and organizations representing patients, providers, laboratories and diagnostic manufacturers called on Senate and House leaders to advance legislation that would reform and modernize the process for bringing innovative diagnostics and clinical laboratory tests to ma

The American Cancer Society Cancer Action Network joined 77 other organizations in a letter to leadership in the U.S.

ACS CAN supports the coverage of FDA-approved NGS panels, and also supports the coverage of panels used as part of NCI clinical trials.  CMS is encouraged to reconsider limitations on patient eligibility and is urged to create clear and achievable requirments for evidence development.